Commentary: Mendelian randomization and gene-environment interaction.

1 Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986;i:507–08. Reprinted Int J Epidemiol 2003;32:xx–xxx. 2 Youngman LD, Keavney BD, Palmer A et al. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by ‘Mendelian andomization’. Circulation 2000;102(Suppl.II):31–32. 3 Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1–22. 4 Collins R, Peto R, Gray R, Parish S. Large-scale randomised evidence: trials and overviews. In: Weatherall D, Ledingham JGG, Warrell DA (eds). Oxford Textbook of Medicine. Oxford: Oxford University Press, 1996. 5 Gorin NC, Labopin M, Fouillard L et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Bone and Marrow Transplantation (EBMT). Bone Marrow Transplantation 1996;18:111–17. 6 Wheatley K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?—a statistician’s view. Br J Haematol 2002;118:351–56. 7 Burnett AK, Wheatley K, Goldstone AG et al. MRC AML12: a comparison of ADE vs MAE and S-DAT vs H-DAT ± retinoic acid for induction and four vs five courses using chemotherapy or stem cell transplant in consolidation, in 3459 patients under 60 years with AML. Blood 2002;100:155a. 8 Gray RG, Wheatley K. How to avoid bias when comparing bone marrow transplant with chemotherapy. Bone Marrow Transplantation 1991;7(Suppl.3):9–12. 9 Reiffers J, Stoppa AM, Attal M et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996;10:1874–82. 10 Keating S, de Witte T, Suciu S et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. Br J Haematol 1998;102:1344–53. 11 Burnett AK, Wheatley K, Goldstone AH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385–400. 12 Burnett AK, Wheatley K, Stevens R et al. Further data to question the use of alloBMT in AML CR1 in addition to intensive chemotherapy. The MRC experience in 715 patients under 44 years with donors available. Blood 2002;100:74a. 13 Woods WG, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the children’s cancer group. Blood 2001; 97:56–62. 14 Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649–56. 15 Tsimberidou A-M, Stavroyianni N, Viniou N et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97:1721–31. 16 Bleakley M, Lau L, Shaw PJ, Kaufman A. Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. Bone Marrow Transplantation 2002;29:843–52. 17 Mantel N, Byar DB. Evaluation of response time data involving transient states: an illustration using heart-transplantation data. J Am Statist Assoc 1974;69:81–86.

[1]  M. B. Katan,et al.  Apolipoprotein E isoforms, serum cholesterol, and cancer , 2004 .

[2]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[3]  D. Kang,et al.  Influence of GSTM1 genotype on association between aromatic DNA adducts and urinary PAH metabolites in incineration workers. , 2002, Mutation research.

[4]  Tianxia Wu,et al.  Interaction between a single nucleotide polymorphism in the alcohol dehydrogenase 3 gene, alcohol consumption and oral cancer risk , 2002, International journal of cancer.

[5]  P. Porter,et al.  Oral squamous cell cancer risk in relation to alcohol consumption and alcohol dehydrogenase-3 genotypes. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  M. Teh,et al.  Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  M. Spitz,et al.  Alcohol dehydrogenase 3 genotype is not associated with risk of squamous cell carcinoma of the oral cavity and pharynx. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  T. Omori,et al.  Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. , 2001, Carcinogenesis.

[9]  John D. Potter,et al.  Food, nutrition and the prevention of cancer : a global perspective , 2001 .

[10]  M. Spitz,et al.  Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  P. Dayer,et al.  Role of alcohol dehydrogenase 3 and cytochrome P‐4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract , 2000, International journal of cancer.

[12]  G. Coetzee,et al.  Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China , 2000, The Lancet.

[13]  K K Kidd,et al.  Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. , 1999, American journal of human genetics.

[14]  M. Spitz,et al.  Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. , 1998, Journal of the National Cancer Institute.

[15]  Abelardo Avila-Curiel,et al.  Food, nutrition and the prevention of cancer: a global perspective , 1998 .

[16]  R. Hayes,et al.  Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. , 1997, Journal of the National Cancer Institute.

[17]  P. Couzigou,et al.  Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms , 1997, Human Genetics.

[18]  S. Hecht,et al.  Chemoprevention of lung cancer by isothiocyanates. , 1996, Advances in experimental medicine and biology.

[19]  G. Taubes.  Epidemiology faces its limits. , 1995, Science.

[20]  C. Sing,et al.  Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. , 1985, American journal of human genetics.

[21]  Ting-kai Li,et al.  Relationship between kinetics of liver alcohol dehydrogenase and alcohol metabolism , 1983, Pharmacology Biochemistry and Behavior.

[22]  A. Olshan,et al.  Pooled analysis of alcohol dehydrogenase genotypes and head and neck cancer: a HuGE review. , 2004, American journal of epidemiology.

[23]  J. Mission,et al.  Textbook of Cancer Epidemiology , 2004 .

[24]  A. Olshan,et al.  Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. , 2001, Carcinogenesis.

[25]  R. Gray,et al.  How to avoid bias when comparing bone marrow transplantation with chemotherapy. , 1991, Bone marrow transplantation.

[26]  On Chemotherapy. , 1924, Canadian Medical Association journal.